Samantha J Mayo1,2, Isabel Wozniczka3,4, Sarah Brennenstuhl3, Sean B Rourke5,6, Doris Howell3,4, Kelly A Metcalfe3,7, Jeffrey H Lipton4,8. 1. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. samantha.mayo@utoronto.ca. 2. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. samantha.mayo@utoronto.ca. 3. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. 4. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 5. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada. 6. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 7. Women's College Hospital Research Institute, Toronto, Ontario, Canada. 8. Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
CONTEXT: Survivors of allogeneic hematopoietic stem cell transplantation (alloHCT) may experience cognitive impairment over time post-treatment, but early identification of these individuals is limited. OBJECTIVES: We previously reported a prospective evaluation of cognitive functioning over the first 6 months of alloHCT. Here, we report an extension of this study, with specific aims to (1) evaluate the trajectory of cognitive outcomes over the first 6 years post-alloHCT, and (2) determine the extent to which late cognitive impairment is predicted by earlier impairment. METHODS: Participants completed objective and subjective cognitive measures before alloHCT, and at 100 days, 6 months, and 6 years post-alloHCT. Outcome trajectories were determined using linear mixed effects models. Relationships between early and late cognitive impairment were assessed using logistic regression and receiver operator curves. RESULTS: This analysis is based on longitudinal data from 59 participants, of whom 20 provided data at 6-year follow-up. Longitudinal models revealed an overall stability of cognitive outcomes over time, except for psychomotor efficiency/processing speed performance, which significantly improved (p = .049). However, poor learning/memory and cognitive complaints were persistently observed. At 6 years, 40% of relapse-free survivors met the impairment criteria. Impairment at 100 days was associated with impairment 6 years (OR = 20.00, p = .028) and demonstrated good accuracy in classifying those who were impaired and not impaired at 6 years (AUC = .79; 95% CI = .56-1.00). CONCLUSION: Poor cognitive outcomes among long-term alloHCT survivors are associated with cognitive functioning during the early post-treatment period. Early identification of survivors likely to experience poor cognitive outcomes may be possible, enabling timely intervention to mitigate long-term negative impacts.
CONTEXT: Survivors of allogeneic hematopoietic stem cell transplantation (alloHCT) may experience cognitive impairment over time post-treatment, but early identification of these individuals is limited. OBJECTIVES: We previously reported a prospective evaluation of cognitive functioning over the first 6 months of alloHCT. Here, we report an extension of this study, with specific aims to (1) evaluate the trajectory of cognitive outcomes over the first 6 years post-alloHCT, and (2) determine the extent to which late cognitive impairment is predicted by earlier impairment. METHODS:Participants completed objective and subjective cognitive measures before alloHCT, and at 100 days, 6 months, and 6 years post-alloHCT. Outcome trajectories were determined using linear mixed effects models. Relationships between early and late cognitive impairment were assessed using logistic regression and receiver operator curves. RESULTS: This analysis is based on longitudinal data from 59 participants, of whom 20 provided data at 6-year follow-up. Longitudinal models revealed an overall stability of cognitive outcomes over time, except for psychomotor efficiency/processing speed performance, which significantly improved (p = .049). However, poor learning/memory and cognitive complaints were persistently observed. At 6 years, 40% of relapse-free survivors met the impairment criteria. Impairment at 100 days was associated with impairment 6 years (OR = 20.00, p = .028) and demonstrated good accuracy in classifying those who were impaired and not impaired at 6 years (AUC = .79; 95% CI = .56-1.00). CONCLUSION: Poor cognitive outcomes among long-term alloHCT survivors are associated with cognitive functioning during the early post-treatment period. Early identification of survivors likely to experience poor cognitive outcomes may be possible, enabling timely intervention to mitigate long-term negative impacts.
Authors: S Mayo; H A Messner; S B Rourke; D Howell; J C Victor; J Kuruvilla; J H Lipton; V Gupta; D D Kim; C Piescic; D Breen; A Lambie; D Loach; F V Michelis; N Alam; J Uhm; L McGillis; K Metcalfe Journal: Bone Marrow Transplant Date: 2016-02-29 Impact factor: 5.483
Authors: Samantha J Mayo; Hans A Messner; Sean B Rourke; Doris Howell; J Charles Victor; Jeffrey H Lipton; J Kuruvilla; Vikas Gutpa; Dennis Dong Hwan Kim; Fotios V Michelis; Kelly Metcalfe Journal: Bone Marrow Transplant Date: 2019-11-19 Impact factor: 5.483
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: Karen L Syrjala; Samantha B Artherholt; Brenda F Kurland; Shelby L Langer; Sari Roth-Roemer; JoAnn Broeckel Elrod; Sureyya Dikmen Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Debra Lynch Kelly; David Buchbinder; Rafael F Duarte; Jeffrey J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary E Flowers; Bipin Savani; Bronwen E Shaw Journal: Biol Blood Marrow Transplant Date: 2017-09-20 Impact factor: 5.742
Authors: Lucette A Cysique; Donald Franklin; Ian Abramson; Ronald J Ellis; Scott Letendre; Ann Collier; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2011-03-07 Impact factor: 2.475
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: K M Phillips; H L McGinty; J Cessna; Y Asvat; B Gonzalez; M G Cases; B J Small; P B Jacobsen; J Pidala; H S L Jim Journal: Bone Marrow Transplant Date: 2013-05-06 Impact factor: 5.483